drugset / Trial / NCT04865029

Estradiol and Progesterone in Hospitalized COVID-19 Patients

NCT04865029 ↗

Phase 2 Terminated 10 enrolled Tulane University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine to what extent a short systemic steroid therapy with estradiol and progesterone, administered early to hospitalized and confirmed COVID-19 positive patients of both sexes in addition to standard of care (SOC) can reduce the severity of symptoms and outcomes compared to SOC alone.

Timeline

Start
2021-07-22
Primary completion
2022-01-25
Completion
2022-01-25

Outcome

Missed primary endpoint

Stopped (Enrollment): “Lack of enrollment due to change of COVID 19 variant prevalence”

paper There were no significant changes between the groups in primary outcome, LOS, DOT, RR or AEs. PMID 39349554 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Cypionate Small molecule 5 mg Intramuscular
Subject Progesterone Other / unclassified 200 mg Oral

Indications